May 03, 2011 01:31 PM IST | Source: CNBC-TV18

Strides, Pfizer to deal post US FDA nod on Oncology unit

Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings in the next few weeks.

Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings with the US FDA over the next few weeks.

40 oncology drugs have been out licensed to Pfizer, and Kumar further confirms that the Pfizer partnership is the most impactful. He also says that this approval allows the company to operate in a niche space within US.

Below is a verbatim transcript of Arun Kumar

Follow us on
Available On